Anchiano Therapeutics Ltd. (ANCN) SEC Filing 8-K Material Event for the period ending Tuesday, May 5, 2020

Anchiano Therapeutics Ltd.

CIK: 1534248 Ticker: ANCN

View differences made from one to another to evaluate Anchiano Therapeutics Ltd.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Anchiano Therapeutics Ltd..


Assess how Anchiano Therapeutics Ltd.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Anchiano Therapeutics Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Anchiano Therapeutics Ltd. provided additional information to their SEC Filing as exhibits

Ticker: ANCN
CIK: 1534248
Form Type: 8-K Corporate News
Accession Number: 0001104659-20-057049
Submitted to the SEC: Tue May 05 2020 7:50:23 PM EST
Accepted by the SEC: Wed May 06 2020
Period: Tuesday, May 5, 2020
Industry: Pharmaceutical Preparations
  1. Event for Officers
  2. Financial Exhibit
  3. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: